Cramer makes the call on viewers' favorite stocks.   Read More

If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.   Read More

Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?   Read More

What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.    Read More